Evidence for thiazolidinedione, insulin sensitizers in the treatment of type 2 diabetes mellitus
Journal
Journal of Internal Medicine of Taiwan
Journal Volume
18
Journal Issue
1
Pages
11-19
Date Issued
2007
Author(s)
Abstract
In Taiwan, the epidemiological research had showed increasing prevalence of hyperglycemia in general population, including adolescent. Previous studies showed that life style intervention could play a pivotal role to prevent ongoing diabetes mellitus in together with certain oral medication. Amongst, insulin sensitizers have different pharmacological mechanism from conventional oral hypoglycemic agents. Insulin sensitizers can not only improve blood glucose control, but decrease insulin resistance via activation peroxisome proliferator-activated receptors, PPARs. This review will focus on recent evidence-based data for insulin sensitizers to elucidate several important issues, including their side effects, pharmacological mechanism, pharmacokinetics, and pharmacoeconomics.
SDGs
Other Subjects
2,4 thiazolidinedione derivative; adiponectin; C reactive protein; insulin sensitizing agent; metformin; peroxisome proliferator activated receptor; pioglitazone; rosiglitazone; sulfonylurea; troglitazone; clinical trial; drug metabolism; evidence based medicine; glucose blood level; human; insulin sensitivity; non insulin dependent diabetes mellitus; nonalcoholic fatty liver; review; Taiwan; unspecified side effect
Type
review